Summary:
- Merck and Moderna are collaborating on a new mRNA vaccine for lung cancer that is currently in phase 3 clinical trials.
- The vaccine is designed to target specific mutations in lung cancer cells and stimulate the immune system to attack and destroy those cells.
- If successful, this vaccine could be a significant breakthrough in the treatment of lung cancer, which is one of the most deadly forms of cancer.